Table 2.
Clinical remission of the MN patients by intention-to-treat analysis
| Cyclosporin + Sirolimus (n = 37) | Cyclosporin monotherapy (n = 37) | OR (95% CI) | |
|---|---|---|---|
| Complete remission (CR), n (%) | |||
| 3 months | 2/37 (5.4) | 1/37 (2.7) | 2.11 (0.18–23.72) |
| 6 months | 2/36 (5.6) | 2/36 (5.6) | 1.00 (0.13–7.51) |
| 12 months | 5/36 (13.9) | 5/36 (13.9) | 1.00 (0.26–3.80) |
| Partial remission (PR), n (%) | |||
| 3 months | 14/37 (37.8) | 17/37 (45.9) | 0.72 (0.28–1.81) |
| 6 months | 25/36 (69.4) | 24/36 (66.7) | 1.13 (0.42–3.06) |
| 12 months | 21/36 (58.3) | 19/36 (52.8) | 1.25 (0.49–3.18) |
| Composite remission (CR + PR), n (%) | |||
| 3 months | 16/37 (43.2) | 18/37 (48.6) | 0.80 (0.32–2.01) |
| 6 months | 27/36 (75.0) | 26/36 (72.2) | 1.15 (0.40–3.30) |
| 12 months | 26/36 (72.2) | 24/36 (66.7) | 1.30 (0.48–3.56) |
The intention-to-treat population included all the patients who underwent randomization and received treatments. The primary outcome was clinical remission (CR + PR) at 12 months